China's SFDA approves TPI anti-diabetic drug Gliclazide

Download PDF Copy

May 13 2011

NewsGuard 100/100 Score

Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets (80 mg formulation).

Gliclazide is an oral anti-diabetic drug that is used for the control of hyperglycemia in gliclazide-response diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset. It is used when diabetes could not be managed by proper dietary adjustment and exercise or when not suitable for insulin therapy.

TPI is anticipating that its Gliclazide Tablets to make its market entry in July this year.

SOURCE Tianyin Pharmaceutical Co., Inc.

Posted in: Medical Condition News | Pharmaceutical News

Tags: Biopharmaceutical, Blood Sugar, Calcium, Cell, Diabetes, Diabetes Mellitus, Diet, Endocrinology, Exercise, Hyperglycemia, Insulin, Ketosis, Medicine, Neuropathy, Obesity, Pancreas, Peripheral Neuropathy, Pharmaceuticals, Potassium, Sulfonylurea, Type 2 Diabetes

Comments (0)

Download PDF Copy

Suggested Reading

Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes

Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes

Rare variant analysis reveals genetic spectrum of monogenic diabetes genes

Rare variant analysis reveals genetic spectrum of monogenic diabetes genes

Spermidine regulates RIPK1 to combat diabetes and vascular damage

Spermidine regulates RIPK1 to combat diabetes and vascular damage

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Study reveals slower fat gain in babies exposed to gestational diabetes

Study reveals slower fat gain in babies exposed to gestational diabetes

New therapy from UI Health becomes the first FDA-approved treatment for brittle type 1 diabetes

New therapy from UI Health becomes the first FDA-approved treatment for brittle type 1 diabetes

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients

SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Mapping human biology: Human Cell Atlas leads a new era in precision medicine